# Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients

> **NCT00150345** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 147 (actual)

## Conditions studied

- Possible Fungal Infection

## Interventions

- **DRUG:** voriconazole (Vfend)
- **DRUG:** voriconazole (Vfend)

## Key facts

- **NCT ID:** NCT00150345
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2012-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150345, "Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00150345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*